Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1438-1444

  Wieland, Ulrike ^a   Brockmeyer, Norbert H ^b   Weissenborn, Soenke J ^a   Hochdorfer, Bettina ^b   Stücker, Markus ^b   Swoboda, Jochen ^c   Altmeyer, Peter ^b   Pfister, Herbert ^a   Kreuter, Alexander ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Institute of Cytology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ANUS TUMOR; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG DOSAGE FORM; EPITHELIUM TUMOR; EROSION; ERYTHEMA; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; TREATMENT RESPONSE; VIRUS TYPING; WART VIRUS;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CARCINOMA IN SITU; DNA, VIRAL; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SUPPOSITORIES; TREATMENT OUTCOME;

EID: 33751205325     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1438     Document Type: Article

References (37)

1. Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr. 1998;23:15-20.
2. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIVinfected individuals. Dermatol Ther. 2005;18:67-76.
3. Panther LA, Schlecht HP, Dezube BJ. Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read. 2005;15:79-91.
4. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177:361-367.
5. Lacey HB, Wilson GE, Tilston P, et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect. 1999;75:172-177.
6. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407-1414.
7. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31:96-99.
8. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37:1563-1565.
9. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg. 2004;30:1101-1112.
10. Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16:85-89.
11. van Poelgeest MI, van Seters M, van Beurden M, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res. 2005;11:5273-5280.
12. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infect Dis. 2001;1:189-198.
13. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. 2005;125:1-8.
14. Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol. 2003;149(suppl 66):9-14.
15. Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. Br J Surg. 2005;92:277-290.
16. Berry JM, Palefsky JM, Welton ML. Anal cancer and its precursors in HIV-positive patients: perspectives and management. Surg Oncol Clin N Am. 2004;13:355-373.
17. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002;45:453-458.
18. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum. 2005;48:1042-1054.
19. Kreuter A, Hochdorfer B, Stücker M, et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol. 2004;50:980-981.
20. Kreuter A, Brockmeyer N, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol. 2005;52:603-608.
21. Fenger C, Nielsen VT. Precancerous changes in the anal canal epithelium in resection specimens. Acta Pathol Microbiol Immunol Scand A. 1986;94:63-69.
22. Luff RD. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. Am J Clin Pathol. 1992;98:152-154.
23. Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol. 2002;147:757-759.
24. Wieland U, Jurk S, Weissenborn S, Krieg T, Pfister H, Ritzkowsky A. Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol. 2000;115:396-401.
25. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791-795.
26. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779-787.
27. Weissenborn SJ, Funke AM, Hellmich M, et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol. 2003;41:2763-2767.
28. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
29. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-1510.
30. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:314-319.
31. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-1134.
32. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol. 2001;137:14-16.
33. Gutzmer R, Kaspari M, Vogelbruch M, et al. Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br J Dermatol. 2002;147:160-165.
34. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis. 1998;178:551-555.
35. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 1999;43:55-63.
36. Arrese J, Paquet P, Claessens N, Pierard-Franchimont C, Pierard G. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol. 2001;28:131-134.
37. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5:156-164.